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Abstract 
Gamma-secretase is a trans-membrane aspartyl protease that consists of four subunits, 
namely Anterior Pharynx Defective Phenotype (APH-1), Presenilin (PSEN), Nicastrin 
(Nct) and Presenilin 2 Enhancer (PEN2). Presenilin is identified as the catalytic core of 
gamma-secretase with the two aspartyl residues at the catalytic site. Gamma-secretase is 
involved in the ultimate step in the processing of Amyloid Precursor Protein (APP) to 
yield Amyloid Beta peptide (Aβ).  Aβ of various residue lengths is formed that includes the 
toxic Aβ42. Aggregation of Aβ42 has been identified to contribute to etiology of 
Alzheimer’s disease (AD). Inhibition of processing of APP by gamma-secretase is a 
possible intervention strategy for the therapy for AD. Various studies carried out to find 
inhibitors for gamma-secretase have populated two classes of compounds, Gamma-
secretase Inhibitors (GSI) and Gamma-secretase Modulators (GSM). Despite these efforts 
there is a dearth of an effective therapy for AD. This study aimed to find potential 
inhibitors of gamma-secretase using in-silico screening of DrugBank database. A total of 
10 Pharmacophore models were developed from 54 molecules shown to inhibit gamma-
secretase. The pharmacophore models were used as 3D query in database screening of 
6160 drug molecules selected from DrugBank. The list of hits that resulted from the 
database screening using all the 10 pharmacophore models was compacted to yield 721 
unique entries with a fit score over 3.00 on a scale of 4.00 against the pharmacophore 
model. A QSAR model was developed employing multiple linear regression to calculate 
the predicted IC50 value for the 721 molecules from screening using pharmacophore 
models. Docking study was done to calculate the binding energy for 498 molecules with 
predicted IC50 value under 10000nM. 55 molecules with binding energy, ∆G, lesser than  
–8.00 kcal/mol are presented as potential inhibitors of gamma-secretase. Thus, this data 
can be used for further studies for the development of therapy for Alzheimer’s disease. 
Table of Contents 
1 Introduction        1 
1.1 Protein Folding and its regulation     1 
1.2 Protein Misfolding and Amyloidogenesis    3 
1.3 Amyloidoses         5 
1.4 Alzheimer’s disease and gamma secretase    6 
1.5 Therapy for Alzheimer’s disease     7 
1.6 In-silico screening in drug discovery     7 
1.7 Pharmacophore modeling      8 
1.8 Quantitative Structure-Activity Relationship (QSAR)  9 
1.9 Docking method        9 
1.10 Objective of the study       10 
2 Literature Review        11 
3 Methods         20 
3.1 Dataset Collection        20 
3.2 Feature Mapping        20 
3.3 Pharmacophore modeling      21 
3.4 Database Selection        22 
3.5 Local Database Creation       22 
3.6 Database Screening       25 
3.7 Activity prediction using QSAR     25 
3.8 Calculation of Molecular descriptors     26 
3.9 Selection of Molecular descriptors     26 
3.10 Multiple Linear Regression      27 
3.11 Developing QSAR model to predict IC50    28 
3.12 Docking study with SwissDock      28 
4 Results         30 
4.1 Pharmacophore Modeling      30 
4.2 Database Screening       32 
4.2.1 Pharmacophore search       32 
4.3 Activity prediction using QSAR     32 
4.4 Docking study        46 
4.4.1 Binding site definition       46 
4.4.2 Docking using SwissDock      46 
5 Discussion         52 
6 References         53 
 
List of Figures 
Figure 1 - Structure of compounds in training set. The two-dimensional chemical 
structure of 56 compounds taken in the training set. The ChEMBL Id for the compounds 
has been used to denote the compounds.      23 
 
Figure 2 - Pharmacophore hypotheses generated. The input of 56 training set 
molecules gave 10 pharmacophore hypotheses. The pharmacophore hypotheses have 
hydrophobic, HY (cyan) and hydrogen bond acceptor, HBA (green). The total no. of 
features in each hypothesis is 4 (2 HY, 2 HBA).     31 
 
Figure 3 - Plot of Actual activity data (log IC50) vs Predicted activity data (log IC50)
           40 
 
Figure 4 - Binding site with Asp 385 predicted using QsiteFinder on the CTF of 
presenilin (2KR6). The binding site’s surface is marked in purple, while Asp 385 is marked 
in cyan.          46 
 
Figure 5a & 5b – Hits of docking study and estimated free energy of binding screen, 
∆G <= -8.00 kcal/mol for the compounds with predicted IC50 <=10000nM          47, 48 
 
 
List of Tables 
Table 1 - Training dataset for pharmacophore modelling for potential inhibitors of 
gamma-secretase showing experimental activity (IC50) and the total no. of pharmacophore 
features (Note - Exp.-Experimental, P.-Pharmacophore)    24 
 
Table 2 - Pharmacophore hypotheses generated with the features present in the 
pharmacophore model and the maximum fit score along with the rank of each hypotheses.
           30 
 
Table 3 – List of compounds screened from DrugBank using the pharmacophore 
hypotheses with Fit value > 3.0000 while 4.0000 is the maximum fit value  33 
 
Table 4 – Training Set compounds of QSAR model development with activity (IC50) 
and molecular descriptor data (Sv, Mv, Me, Mp, nBt, nCIC, Hy, MLogP, ALogP) 38 
 
Table 5 - Molecular descriptors used in QSAR model along with its coefficient and 
input data range         39 
 
Table 6 - Validation of QSAR model. Actual activity data (log IC50) and Predicted 
Activity data (log IC50)        40 
 
Table 7 – Predicted IC50 values of the hits of pharmacophore screen of DrugBank 
compounds          41 
 
Table 8 – Result of docking study showing estimated free energy of binding for the 




Proteins are the cogs that make the cell machinery tick. Proteins are involved in 
every aspect of cell function namely structure, motion, catalysis, recognition and 
regulation. The cellular membrane is embedded with membrane proteins that act as 
receptors, channels for a variety of molecules. These proteins thus enable signal 
transduction and transport of molecules into and out of the cell. Enzymes are proteins that 
act as catalysts in many processes and pathways in the cell. Also a number of enzymes are 
known to regulate various cellular processes and pathways by activating and deactivating 
other molecules involved in the processes. Antibodies are also proteins that are part of the 
immune response system that help to maintain immunity against foreign bodies. Signal 
transduction occurs due to the participation of trans-membrane proteins that act as 
receptor channels for the transport of the signaling molecules across the cell membrane. 
These are a few of the innumerous class of proteins involved in the complex machinery in 
the cell.  
 
1.1 Protein Folding and its regulation 
Self-assembly is one of the most intricate processes of the living system. A classic 
example of this self-assembly is the folding of proteins into three-dimensional structures. 
The bringing-together of the functional groups in vicinity to one-another in a highly 
specific structures result from protein folding aid in the possibility of diversity as well as 
selectivity in the chemical processes. Many biological activities are coupled to the correct 
folding of proteins that include molecular trafficking, regulation of growth and 
differentiation of the cell. Thus only a correctly folded protein has a long-term in the 
biological environment.  The most thermodynamically structures of proteins always 
correspond to the native state of the protein(1).  It is established that folding of a protein 
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does not involve the systemic search of all the possible conformations but a stochastic 
search of the conformations accessible to the chain of polypeptide(2). The right energy 
landscape, encoded by the amino acid sequence of the protein, which is in turn, is 
determined by the genetic code that has evolved for rapid and efficient folding of the 
protein, enables the scan of a small number of all possible conformations in order for the 
coil to transition into a native structure.  This energy landscape approach to protein 
folding shows that the transition states for folding are critical regions of energy surfaces 
through which all molecules must pass to reach the folded native state(3). 
The results of many studies show the formation of nucleus from a small number of 
residues, over which the rest of the structure condenses, as the fundamental mechanism of 
protein folding(4). An important element in the folding process is the formation of 
secondary structure that is stabilized by hydrogen bonding between the amide and 
carbonyl groups of the peptide main chain. Studies involving the structural properties of 
the intermediate or transition states show that a full native structure is obtained only when 
native-like interactions both within and between the domains have been formed(2). This is 
achieved by close packing and locking of side chains and exclusion of water molecules 
from protein core.  
Folding of proteins in vivo has been established to be co-transitional in a few 
cases, which implies that the protein synthesis and folding occur simultaneously. In other 
cases the proteins fold in the cytoplasm or after trafficking and translocation through the 
membranes in mitochondria or the endoplasmic reticulum. In order to regulate the folding 
of proteins several molecular chaperones present in the cell are brought into play. These 
molecular chaperones interact with the nascent chain of protein as soon as they emerge 
from the ribosomes or later. Molecular chaperones do not act as catalysts for the steps in 
protein folding but increase the effectiveness of these steps by reducing the probability of 
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the competing reactions such as aggregation.  The mechanism of action of the chaperones 
can be illustrated with the chaperonin GroEL and its co-chaperone Gro-ES. These have 
been shown to protect the protein from the external environment by allowing the 
incompletely folded protein to enter its cavity and then fold into native structure(5). It is 
also suggested that molecular chaperones are able to rescue misfolded proteins and 
aggregated proteins enabling them to have another chance at folding correctly. Also 
available are a class of folding catalysts such as protein disulfide isomerases, peptidylprolyl 
isomerases(6). The proteins destined for secretion undergo a quality control check in the 
endoplasmic reticulum. The mechanism of quality control involves glycosylation and 
deglycosylation reactions to enable correctly folded proteins to be distinguished from 
misfolded proteins.   The incorrectly folded proteins initiate an ‘unfolded protein response’ 
in which they are ubiquitinated and then degraded by proteasomes in the cytoplasm. 
 
1.2 Protein Misfolding and Amyloidogenesis 
It is understood that proteins need to be folded correctly to survive in the cell and 
carry out its function. It is also evident that both folding and unfolding are taken as ways 
of generating and abolishing cellular activities. The precursor to the protein degradation is 
unfolding(7). An intrinsic property of proteins is misfolding that happen continuously and 
is influenced by the sequence of amino acids. .Mutations in the amino acid sequence are 
said to accelerate misfolding. In addition, environmental changes such as increased 
temperature, low or high pH, presence of oxidative reagents or high glucose level cause the 
loss of native conformation in proteins rapidly, while being termed denaturation. This 
results in unfolding of the protein. The unfolded proteins are not functional. Also the 
unfolded state is thermodynamically unstable and unfavorable. In an attempt to seek lower 
energy level and higher stability, these proteins have aggregation propensity.  Aggregation 
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starts with nucleation in which the proteins attach reversibly onto a core that is growing, 
termed the nucleus, followed by irreversible attachment of proteins once the critical mass 
of the nucleus crosses the threshold to form a larger aggregate. The concentration of the 
monomers also determines the onset of aggregation. When the concentration of the 
monomer is low, the monomeric state is favored while at high concentration the 
aggregated state is favored as it presents a large energy barrier for resolution (8). Thus the 
aggregates are highly stable. Protein segments that have hydrophobic residues, low net 
charge and susceptibility to β-sheet formation are thought to initiate aggregation (9), by 
acting as the precursor cores that facilitate aggregation further. The precursor is generated 
from the native structure by means of introduction of misfolded variant, incorrect or 
incomplete proteolysis. Thus, there is introduction of a precursor pool from the partial 
misfolding of the variant protein from which rapid aggregation occurs. 
The structure of the protein aggregates vary from unordered amorphous 
aggregates to highly ordered fibrils. These highly ordered fibrils are termed as amyloid. The 
amyloid conformation is stable yet reversible. The amyloids are rich in cross-β structure. It 
consists of non-branched, linear fibrils of protein or peptide. X-ray analysis revealed that 
the β strands are arranged perpendicular to the fibril axis(10). Recent studies reveal the 
presence of parallel(11) or antiparallel(12) β-sheet conformation. Thus, confirming that 
amyloids fibrils have no universal tertiary and quaternary structures. Amyloids show 
conformational plasticity by adopting more than one stable tertiary fold due to which 
conformational differences exist within the fibril formed from a single polypeptide.  
Amyloid proteins are believed to be non-functional proteins while in some 
instances have been associated with physiological function, for example, fibrils of curlin in 
Escherichia coli mediate binding of bacterium to host. A large number of proteins, tau, 
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amyloid β, prion, insulin, α-synuclein and lysozyme to name a few, have been identified to 
undergo misfolding to form amyloids and result in misfolding diseases.  
1.3 Amyloidoses 
The group of protein misfolding diseases where there is accumulation of protein 
aggregates systemically or locally in certain tissues or organs is termed amyloidosis.  The 
characteristic feature of the amyloidoses is the presence of plaques or inclusion bodies. 
The conditions for the development of the disease are not yet fully studied.  These diseases 
can be systemic or localized based on the location of occurrence of the protein aggregates. 
The symptoms depend on the protein involved and the site or organ or aggregation of the 
protein. Diagnosis of the diseases requires histological analysis followed by the definition 
of the amyloidosis. Efficient therapy is not available for most of the amyloidoses.  
It is evident that the aggregates from proteins and peptides can be toxic to the cells 
or deviate from the function of the native protein. The amyloid fibrillar aggregates were 
earlier thought to be involved in the pathogenesis of a number of amyloidoses. Evidence 
has been piling-up on the involvement of the prefibrillar aggregates(13), oligomers(14) and 
not-native monomers(15) in exhibition of toxicity in the cells or tissues. Despite the lack of 
complete mechanism of various diseases and the cause for toxicity to cells or tissue, it can 
be said that the conversion proteins from soluble to insoluble state results in a population 
of non-native structures. The toxicity of these misfolded species tends to arise from the 
fact that the hidden groups that are normally buried are exposed and dispersed. Small 
aggregates are relatively more toxic that mature fibrils as these have a higher proportion of 
surface residues(16). These non-native structures are supposed to trigger a number of 
uncharacteristic events on its interaction with the various molecules and components of 
the cell. Hence are likely to cause malfunction in the cell machinery resulting in the 
diseased condition. Also the damage to the architecture of the tissue brought forward by 
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the accumulation of the aggregates is supposed to be the reason of pathogenesis in a few 
diseases(17).  
A number of human diseases have been classified as amyloidoses namely 
Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Dementia with Lewy 
bodies, lysozyme amyloidosis, fibrinogen amyloidosis, AA amyloidosis, AL amyloidosis, 
cataract and cutaneous lichen amyloidosis.  
1.4 Alzheimer’s disease and gamma secretase 
Alzheimer’s disease is an irreversible, progressive brain disease that slowly destroys 
memory and thinking skills, and eventually even the ability to carry out the simplest tasks. 
In most people with Alzheimer’s, symptoms first appear after age 60. It was estimated that 
35.6 million around the world may have Alzheimer’s disease in 2010; 65.7 million by 2030 
and 115.4 million by 2050(18). Alzheimer’s disease is the most common cause of dementia 
among older people. Dementia is the loss of cognitive functions which ranges in severity 
from mild to aggressive. In 1906, Dr. Alzheimer noticed changes in the brain tissue of a 
woman who had died of an unusual mental illness. Her symptoms included memory loss, 
language problems, and unpredictable behavior. After she died, he examined her brain and 
found many abnormal clumps (now called amyloid plaques), tangled bundles of fibers 
(now called neurofibrillary tangles) and the loss of connections between nerve cells 
(neurons) in the brain. Hence, Alzheimer’s disease is named after Dr. Alois Alzheimer.   
In Alzheimer’s disease, senile plaques are formed by accumulation of aggregates of 
40- to 42-amino acid long, 39- and 43-aa peptides have also been described, amyloid-β 
(Aβ) peptide. Amyloid-β is formed by cleaving amyloid precursor protein (APP) by β- and 
γ-secretases. The cleavage of APP by γ-secretase produces a 42 amino acid Aβ-42 or a 40 
amino acid Aβ-40 is formed when it occurs in endoplasmic reticulum or trans-Golgi 
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network respectively. APP is involved in various physiological functions while that of Aβ 
peptide have not yet been deduced. In 1991, David Allsop and John Hardy proposed the 
amyloid cascade theory (ACH), according to which the amyloid-β peptide aggregate into 
protein assemblies, which in turn deposit into plaques in the brain that cause 
neurotoxicity(19).  
1.5 Therapy for Alzheimer’s disease 
The current treatments for Alzheimer’s disease are mostly symptomatic, while 
disease-modifying agents are emerging. The symptomatic or palliative treatments attempt 
to compensate for the decreased activity of cholinergic neurons. Various classes of 
compounds such as choline donors (4-Aminopyridine), cholinergic agonists (nicotine 
analogs) and acetyl choline esterase (AChE) inhibitors (donezepil, rivastigmine, 
galantamine) have been developed. The disease modifying drugs are developed to decrease 
the concentration of Aβ. This is done by inhibition of β- and γ- secretases. Also Aβ can be 
degraded or excreted and cleared from the cell to decrease its concentration in theory. In 
another approach the aggregation of Aβ can be inhibited. Inhibition of tau protein’s 
hyperphosphorylation by inhibiting the enzymes involved namely tau protein kinase I and 
II, extracellular signal-regulated kinase. Also drugs are also being developed that inhibit 
excitotoxicity (propiracetam, oxiracetam, or aniracetam) or act as antioxidants (trans-
resveratol, EGb761, Clioquinol). Thus there is a need for the increased effort in the 
development of therapy for Alzheimer’s disease. 
1.6 In-silico screening in drug discovery 
Drug discovery process consists of several steps namely target identification, lead 
compound screening, lead optimization, ADMET studies, preclinical trial evaluation, 
clinical trials and registration. This process trails behind due to being time-consuming, 
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expensive and inefficient due to the low rate of novel therapeutic discovery. In order to 
increase the overall efficiency of the process new methodologies and technologies are 
being implemented. Computational methods are employed in various areas of research. It 
is estimated that the implementation of computational methods in drug discovery can cut 
the annual cost by 33% and the time required by 30% for developing a new drug. 
Computational techniques are capable of providing information regarding function 
prediction, pathway information, homologue mapping, structural information, chemical 
information and disease association. Also a vast number of resources are available such as 
databases of chemical molecules such as ChEMBL, Therapeutic Target Database (TTD), 
Potential Drug Target Database (PDTD), PubChem, ChEMBLdb, DrugBank and etc. 
In-silico screening or virtual screening has become an established technique for the 
development of hit lead compounds. Virtual screening complements traditional high-
throughput screening (HTS) assays. This technique can act as a filter by eliminating a vast 
majority of non-binding compounds in-silico thereby reducing the number of compounds 
to be tested in vitro, thus, reducing the investment of resources in the early stages of drug 
discovery. It includes a series of techniques such as simple filtering and pharmacophore 
searches to docking and scoring. In-silico screening starts from a database of real 
compounds or a virtual database.  
1.7 Pharmacophore modeling 
A pharmacophore can be described as set of steric and electronic properties 
required for a compound to bind to an active site. It describes the three-dimensional 
arrangement of molecular features. The components of a pharmacophore model are 
hydrogen bond donors, hydrogen bond acceptors, aromatic rings, hydrophobic centers, 




Pharmacophore modeling is the identification of various components of the 
pharmacophore and definition of the components to forma model. Pharmacophore 
modeling can be divided into structure-based and ligand-based approaches. Structure 
based pharmacophore modeling is construction of model from available structural data.  It 
can be further divided into macromolecule-ligand complex based and macromolecule 
based. Thus a pharmacophore model can be developed from a set of active compounds 
without any knowledge of the protein active site or from the active site of the protein 
when the geometry of the active site is available. This model can be used to search a 
compound database, which can hence be screened. 
1.8 Quantitative Structure-Activity Relationship (QSAR) 
QSAR is a way of finding a simple equation that can predict an unknown property 
from the molecular structure of a compound. This is done by curve fitting to find the 
equation coefficients that are weights for known molecular properties termed descriptors. 
A descriptor can be any number that describes some aspect of the molecule. The property 
that is being predicted is termed as activity. A QSAR model is essentially an equation that 
can be developed by various methods such as multiple linear regression, partial least 
squares, linear discriminant analysis, logistic regression, genetic function approximation, k-
nearest neighbor, feed forward back propagation neural network, general regression neural 
network and support vector regression. 
1.9 Docking method 
Docking is the search for the energetically favorable binding pose of a ligand to a 
macromolecular receptor. The aim of the docking program is to accurately predict the 
structure of the ligand-receptor complex enabling the prediction of the binding free energy 
of the complex. Docking has enabled the search through databases of available chemical 
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compounds for ligands to use as therapeutics or in studies. The molecule preparation must 
be performed before docking; it involves the creation of complete molecular model from 
molecular structure file followed by processing of the structure for use in specific docking 
program. The sampling method generates multiple positions of the ligand within the 
receptor such that the ligand is placed using the constraints of the receptor shape and are 
near minimum-energy positions. The three classes of sampling method are rigid ligand 
docking, flexible ligand docking and flexible receptor docking. The scoring method is used 
to compute the binding energy of a ligand to the receptor. The accuracy of the scoring 
function inversely affects the speed of calculation. Thus it is necessary to find a balance in 
choosing the method to be employed. 
1.10 Objective of the study 
The major objectives of the study are 
 To find the potential inhibitors of gamma secretase by screening of a chemical 
database 
 To develop pharmacophore models for use a query to screen the chemical 
database 
 To compute the specific activity of the hits of database screening using 
pharmacophore models 
 To subject a set of compounds filtered based on the predicted specific activity 
to docking study against the receptor, here gamma secretase 
 To put forward a set of compounds filtered based on binding energies 
computed using docking study as potential inhibitors of gamma secretase 
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2 Literature Review 
Alzheimer’s disease is a neurodegenerative disorder where the affected individuals 
exhibit dementia. Affected individuals exhibit progressive and permanent decline in 
memory and cognitive functions. It is difficult to positively diagnose Alzheimer’s disease in 
the early stages as memory loss can have other causes too. However a consistent pathology 
with amyloid aggregates called ‘plaques’ and neurofibrillary tangles, is observed in the brain 
of individuals affected by Alzheimer’s disease(20). These are found in the temporal 
neocortex and hippocampal regions of the affected individual’s brain(21). Of the different 
forms of Alzheimer’s disease the most common form occurs after 6o years of age and is 
sporadic(22). The other form of AD, Familial Alzheimer’s disease (FAD) has onset before 
60 years of age (22). The brain regions involved in learning and memory process of the 
individuals with AD are reduced in size. The areas for episodic memory, attention, 
executive functions, semantic memory, language and spatial orientation deteriorate as the 
disease progresses(23, 24). 
The amyloid plaques and neurofibrillary tangles result from the deposition of 
amyloid-β peptide and hyperphosphorylated tau protein, which lead to neuronal loss and 
neurotoxicity in the affected brain. The mechanism of induction of neurotoxicity by the 
deposition of Aβ peptide is not clear. Oxidative stress is stimulated by Aβ peptide directly 
and indirectly. Aβ peptide reduces metal ions to produce hydrogen peroxide by acting as 
enzymes and also generating free radicals (25-27). Aβ peptide also produces free radicals 
by binding to mitochondrial proteins (28). Aβ peptides generate oxidative stress through 
neuroinflammation. Astrocytes and microglia are activated and participate in the immune 
response to the deposition of amyloid beta peptide. These brain cell types produce reactive 
oxygen species upon activation in addition to chemokines and cytokines leading to cell 
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death(29). Aβ peptide also stimulates microglial cells to produce reactive nitric oxide, by 
inducing the expression of nitric oxide synthase(30), and quinolinic acid, a neurotoxin(31). 
Aβ peptide is produced by the processing of amyloid precursor protein (APP) by 
proteolysis. It then accumulates and eventually deposits into amyloid plaque in the brain. 
This is a primary event in the pathogenesis of AD (22). Along with the secondary events 
namely activation of microglia and astrocytes and formation of neurofibrillary tangles the 
formation of amyloid plaques result in neuronal dysfunction and loss. This hypothesis is 
termed as amyloid cascade hypothesis (ACH)(32). APP is a type I integral membrane 
protein that is expressed widely. It is expressed by the APP gene located on chromosome 
21. It is produced in different isoforms from 695 to 770 amino acids. It is processed by 
secretase enzymes to produce Aβ peptide in two distinct pathways, amyloidogenic and 
non-amyloidogenic. In amyloidogenic pathway the cleavage of soluble APP by β-secretase 
gives soluble β-APP, which are released in to the extracellular matrix(33). It is followed by 
the cleavage of the C-terminal fragment (C99) by γ-secretase which releases Aβ peptide of 
varying lengths with Aβ-40 and Aβ-42 being the most common forms. In non-
amyloidogenic pathway, soluble APP is cleaved by α-secretase to release α-APP into the 
extra-cellular matrix. The cleavage of the resulting C-terminal fragment (C83) by γ-
secretase produces p3 fragment(34). Aβ-42 exists as a monomer, which undergoes 
oligomerisation to form oligomers, proto-fibrils and fibrils.  Aβ-42 aggregates into β-sheet 
fibrillar state or non-β-sheet non-fibrillar state(35, 36). The oligomeric intermediate species 
and the mature fibrils are neurotoxic(37). 
Research has identified the genes responsible for the pathologies namely the 
amyloid precursor protein (APP) and the presenilins, PS1 and PS2 (PSEN1, PSEN2)(38). 
PS1 is central to the γ-secretase complex that cleaves APP and Notch(39). Mutations in 
these genes have been identified in Familial Alzheimer’s disease (FAD). These account for 
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50% of the FAD cases(40).The pathological features of FAD is similar to sporadic AD, 
hence mutations in APP, PSEN1, PSEN2 may have a role in sporadic AD too. So far 33 
mutations in APP, 185 mutations in PSEN1, 13 mutations in PSEN2 have been 
documented at the Alzheimer Disease & Frontotemporal Dementia Mutation 
Database(41) (http://www.molgen.vib-ua.be/ADMutations).  
γ-secretase is a transmembrane aspartyl protease. It exists in the plasma membrane 
as a mature complex. It is a multiprotein complex consisting of Presenilin, Nicastrin, Aph-
1 and Pen-2. It may possess homogeneous activity, as several alternatively spliced variants 
and paralogs of Presenilin and Aph-1 have been identified, or heterogeneous activity. The 
presenilins (PS) form the active catalytic core of the enzyme. PS1 and PS2 are the 
homologs of presenilin that exist in mammals. These have a molecular weight around 
50kDa.  It spans the cellular membrane several times. It has been identified that two 
aspartyl residues Asp 257 and Asp 385 located on transmembrane domains 6 and 7 
respectively are central to the catalytic activity of the enzyme(42). Presenilins are 
synthesized as precursor proteins that are incorporated into a larger complex for 
stabilization. This is accompanied by a proteolytic cleavage of PS by presenilinase(43). This 
results in the formation of two separate fragments N-terminal fragment (NTF) and C-
terminal fragment (CTF). Each has a molecular weight of ~ 30kDa and ~20kDa 
respectively. The second member of the complex Nicastrin (Nct) is a glycosylated 
membrane protein that binds to PS. It is synthesized as a precursor that is transported by 
PS from the endoplasmic reticulum and is required for the stabilization of PS NTF and 
CTF(44). Aph-1 is a multimembrane spanning protein with a molecular weight ~30kDa. It 
is necessary for the transport of Nct to cell surface(45). Pen-2 is a hairpin-like membrane 
protein with a molecular weight of approximately 12kDa(46). The molecular weight of the 
γ-secretase complex is on debate, with estimates from 200-250kDa(47) to ~440kDa(48) 
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and larger. All the four proteins are necessary for the full proteolytic activity of the 
enzyme. Genetic studies or knockdown studies on one or more of the components caused 
the loss of activity of the enzyme. Overexpression of one or more of the proteins but not 
all had no effect on the activity of the enzyme. Overexpression of all the component 
proteins caused a change in the proteolytic activity (48-50). 
In an attempt to develop therapy for Alzheimer’s disease, the proteolytic cleavage 
of APP by γ-secretase has been targeted in various studies. This led to the development 
and discovery of a number of compounds that inhibit or modulate the activity of γ-
secretase. Gamma-secretase inhibitors inhibit the activity of gamma-secretase on not only 
APP but other substrates as well. Administration of potent gamma-secretase inhibitors to 
APP transgenic mice resulted in gastrointestinal toxicity due to the disruption of Notch 
signaling in the ileum(51). Thus the development of compounds that are specific for the 
cleavage of APP was necessary. This gave rise to the class of compounds called gamma-
secretase modulators which spared the cleaving of Notch by gamma-secretase. 
γ-secretase inhibitors include compounds of various classes. These include 
transition state analogs, dipeptidic inhibitors, sulfonamides, kinase inhibitor, NSAIDs(52). 
L-685,458(53), WPE-31-C, LY450139(54), DAPT(55), Imatinib(56), R-flurbiprofen(56), 
sulindac sulfide(57), AZ1136, AZ3303, AZ4800(58), E2012(59), MRK-560 are the 
compounds that belong to the mentioned classes. Also studies have shown potent γ-
secretase inhibitors that include α-hydroxycarbonyl derivatives(60), aryl sulfones(61), 
compounds based on benzobicyclo[4.2.1]nonane core(62), helical D-tridecapeptides(63), 
derivatives of triterpene glycoside(64, 65), fused oxadiazines(66), derivatives of piperidine 
acetic acid(67), azepine derivatives(68) and cyclohexanones(69). The listed are only a 
segment of the compounds that have been reported. The mechanism of inhibition of 
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many of these compounds has not yet been fully understood. Meanwhile the search for 
new drugs utilizing various techniques is continuing. 
Drug discovery and development consists of several steps. It starts with the pre-
discovery, which is necessary to understand the pathogenesis of the disease and the 
pathways involved. It is a knowledge acquiring process which is crucial for treating the 
problem. Then target identification follows in which the molecule that is involved in the 
disease is identified as target that can be affected by a drug molecule. Finally, drug 
discovery begins with the testing of various molecules to find a lead molecule. This has 
been carried out by finding compounds in nature, de novo synthesis of molecules, high-
throughput screening. Lead compounds are tested for Absorption, Distribution, 
Metabolism, Excretion and Toxicological properties. Lead compounds are optimized to 
better its properties. This is done by testing analogues of the leads, leading to the choosing 
of the candidate drug. Also considered are the formulation, delivery mechanism and large-
scale manufacturing. Pre-clinical testing of the candidate drug involves in-vitro and in-vivo 
tests these include testing on animals. The clinical trials take place in four phases. In the 
first phase the drug is tested for safety in humans by testing on healthy human volunteers. 
The drug is tested on a small group of patients in the second phase of clinical trials. The 
third clinical trial phase is extensive where the safety and efficacy of the drug are tested. 
Then the drug is registered for approval with the authority for drug approval. It is followed 
by the final clinical trial phase where it is prescribed to a larger section of the population. 
Computational methods have been taken up for the drug discovery process. This 
has resulted in the faster and less expensive drug discovery. The availability of 
cheminformatics resources such as chemical compound databases, target structure 
databases, in addition to the computational techniques such as molecular modeling, 
molecular simulation, etc. has favored the trend of computational drug discovery. One of 
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the most time and resource consuming processes in drug discovery is screening for hits 
and lead compounds. The advent of virtual or in silico screening aimed at changing that. 
An integral part of drug discovery of late is virtual screening. Virtual screening was 
introduced recently compared to the use of database searching. It was defined as 
‘automatically evaluating very large libraries of compounds’ using computer programs(70). 
This suggests that a library of >1060 compounds can be filtered to manageable number 
using in-silico or virtual screening, while the focus in practical scenarios is on filtering 
combinatorial libraries of targeted compounds and enriched libraries. The success of an in-
silico screen lies in finding new or interesting structures than many hits. Availability of 
datasets, in-silico screening techniques and successful screening techniques has helped this 
method gain attention. The possibility of rapid identification of novel ligands(71), 
biomolecules from natural products(72) have improved this interest.  
Virtual screening can be structure-based(73) or ligand-based(74). Ligand based 
approach is primarily used when the protein structure is absent, while structure-based 
approach is used in the presence of high atomic resolution structural data of the protein. 
Results of various studies indicate that structure-based and ligand-based approaches can 
yield a better result when applied in concert(75, 76). Recently, the successful screening for 
the target MEK1 was reported. It employed both in silico and in vitro methods to identify 
fragments. This result has been suggested for use in drug discovery project(77). In another 
study, a library of small molecules was screened to find drugs that can be combined with 
highly active antiretroviral therapy (HAART) to reactivate dormant viruses. Similarity 
based search was employed to the hits of the screen resulting in the find of 8-methoxy-6-
methylquinolin-4-ol (MMQO) as a successful hit(78). Docking, fragment based search are 
structure-based approaches, while pharmacophore search, QSAR are ligand based 
approaches of in silico screening. 
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Pharmacophore was introduced and defined by Paul Ehrlich in 1909 (79) as ‘ a 
molecular framework that carries the essential features responsible for a drug’s biological 
activity’. It is defined by IUPAC(80) as ‘an ensemble of steric and electronic features that is 
necessary to ensure the optimal supramolecular interactions with the biological target and 
to trigger ( or block ) its biological response’. Superposing a set of active molecules and 
extracting the common chemical features required for bioactivity or probing the 
interaction points between the ligand and the macromolecular target can give a 
pharmacophore model. It is being extensively used in in silico screening as well as de novo 
design.  
Structure-based and ligand-based are the two approaches for pharmacophore 
modeling. Ligand based pharmacophore modeling facilitates the drug discovery in the 
absence of the macromolecule structure. Pharmacophore generation from multiple ligands, 
termed training set, involves creating the conformational space for each ligand in the 
training set to represent conformational flexibility of ligands, and aligning the multiple 
ligands in the training set and determining the essential common chemical features to 
construct pharmacophore models. Structure based pharmacophore modeling involves the 
use of 3D structure of the macromolecular target. Its protocol starts with the analysis of an 
analysis of the complementary chemical features of the active site and their spatial 
relationships, and a subsequent pharmacophore model assembly with selected features. It 
can be further classified into macromolecule–ligand-complex based and macromolecule 
(without ligand)-based. A number of pharmacophore generator programs are available 
namely GASP(81), DISCO(82), HipHop(83), Hypogen(84), GALAHAD, PHASE(85), 
MOE, LigandScout(86), Pocket(87) and GBPM(88) besides a number of academic 
programs. On modeling of a pharmacophore model from a set of active ligands it can be 
used a template to query a 3D chemical database and search for potential ligands termed 
18 
 
hits. This approach faces the challenge of higher false positives and or higher false 
negative. This can be overcome by model optimization by adjusting the tolerance radius 
and position of each pharmacophoric feature. 
QSAR stands for Quantitative Structure-Activity Relationship that describes 
structure-activity relationship in terms of steric properties and physiochemical parameters 
or certain structural features. Thus QSAR can correlate inhibition constants, rate 
constants, and affinities of ligands to binding sites with in a series of compounds. The 
properties of the compounds are termed as descriptors. Lipophilicity, polarizability are 
molecular descriptors. Enzyme inhibition data of the compounds has been studied by 
correlating with physiochemical properties using QSAR. QSAR is based on the 
assumption that different structural properties contribute in a linear additive manner to its 
biological activity. There are several methods available to develop a QSAR model the most 
common being multiple linear regression. In an investigation of inhibition of dihydrofolate 
reductase (DHFR) from E. coli and L. casei by benzylpyrimidines, two equations (QSAR 
models) were generated one for each organism. These models differed on the contribution 
of five substituents of benzyl group to biological activity. This was explained to be due to 
the presence of rigid leucine residue on L. casei DHFR hence it formed a narrow cleft that 
the methionine residue in E. coli DHFR(89). 
Molecular descriptors have been extensively used in deriving structure-activity 
relationships, quantitative structure activity relationships, and machine learning prediction 
models for pharmaceutical agents.  A descriptor is “the final result of a logical and 
mathematical procedure which transforms chemical information encoded within a 
symbolic representation of a compound into an useful number or the result of some 
standardized experiment”. Many programs e.g. PaDEL-descriptor, DRAGON, Molconn-
Z, MODEL, Chemistry Development Kit (CDK), JOELib and Xue descriptor set are 
19 
 
available to calculate physical and chemical descriptors. These methods can be applied to 
derive >3,000 molecular descriptors. These descriptors include constitutional descriptors, 
topological descriptors, RDF descriptors, molecular walk counts, 3D-MoRSE descriptors, 
BCUT descriptors, WHIM descriptors, Galvez topological charge indices and charge 
descriptors, GETAWAY descriptors, 2D autocorrelations, functional groups, atom-
centered descriptors, aromaticity indices, Randic molecular profiles,  electrotopological 
state descriptors, linear solvation energy relationship descriptors, and other empirical and 
molecular properties. 
Docking and scoring are used to identify potential lead candidates. The algorithms 
generate a subset of a collection of compounds with higher affinity against a target 
macromolecule by predicting their binding mode and affinity. Docking algorithms deal 
with the prediction of ligand conformation and orientation with in the specific binding site 
of the receptor. DOCK(90), FlexX(91), GOLD(92), Glide(93), ICM(94), FRED(95) and 
AutoDock(96) are a few of the docking programs available in addition the web-based 
docking  servers. Scoring methods attempt to estimate the bound receptor-ligand complex 
rightness.  Scoring methods make assumptions and oversimplify various physical 
characteristics. This results in the inability of the scoring function to differentiate between 
correct and incorrect poses. Thus giving rise to a number of false positives and false 
negative hits. Docking based screening has been successfully implemented in finding the 
inhibitor for Acetylcholinesterase(97). The initial screening was done for the ACD and 
Maybridge database consisting of 160,000 compounds. The computer program used was 





3.1 Dataset Collection 
The choice of training set is important to the pharmacophore generation process 
as the pharmacophore built is as good as the input data. The following criteria have been 
considered during the selection of data set. All the compounds have to bind to the same 
receptor more or less in the same fashion. The compound data should be widely populated 
over a larger activity range. The most active compounds have to be included in the dataset. 
All biologically relevant data should be obtained for the compounds(84). Each individual 
feature in the resulting pharmacophore will contribute a certain weight proportional to its 
contribution to biological activity. Taking in to account these criteria, 369 gamma-secretase 
inhibitors were sourced from various literature sources and the target database at 
ChEMBL (60-63, 65, 66, 98-109). The 2D structure of the compounds were obtained from 
ChEMBL chemical database(103). 2D structures were converted to 3D structures using 
OpenBabel 2.3.1(110). Next, the compounds were filtered based on No. of violations of 
Lipinski’s rule of five=0 which yielded 206 compounds. Also on filtering compounds with 
IC50 value < 100nM in a range of 0.08nM to 93nM, 56 compounds were obtained. These 
56 compounds were chosen as training set. The chemical structure of the compounds in 
the training set is given in (Figure 1), while their experimental activity (IC50) is given in 
(Table 1) 
3.2 Feature Mapping 
Pharmacophore features are chemical features such as hydrogen bond donors, 
hydrogen bond acceptors, aromatic rings, hydrophobic centers, acidic groups, basic 
groups, planar atoms, CO2 centroid, NCN+ centroid, etc. Pharmacophore features were 
mapped for 56 compounds of the training set using the Feature Mapping protocol in 
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Discovery Studio 2.5(111) The total no. of pharmacophore features among the 
compounds ranged from 8 to 28.(Table 2)  
3.3 Pharmacophore modeling  
The training set consisting of 56 compounds was used to generate pharmacophore 
model. The HipHop(83) Algorithm available in Common Feature Pharmacophore 
Generation protocol tries to generate pharmacophore hypothesis (models) with features 
common amongst the molecules of the training set. During pharmacophore generation a 
minimum of 1 and a maximum of 10 pharmacophore feature such as hydrogen bond 
donor (HBD), hydrogen bond acceptor (HBA), and hydrophobic (HY) were included. All 
the parameters were set to default. The HipHop algorithm scores each configuration based 
on both the degree to which it is common to the input set and its estimated rarity. The 
program begins by identifying configurations of features common to the molecules. More 
precisely, a configuration is a set of relative locations in 3D space, each associated with a 
type of feature. A molecule matches a configuration if it possesses a set of features and a 
conformation such that the set of features can be superimposed with the corresponding 
locations. A set of features is considered superimposed if each feature lies within a 
specified distance, the tolerance, from the corresponding ideal location. Certain molecules 
may be permitted to miss a feature until the total no. of molecules missing a feature does 
not drop below the set limit. The hypotheses are scored by classic maximum likelihood 
rule based on the probability of observed data under the assumption that the hypothesis is 
correct. The rarity of a configuration is estimated by applying regression model for perfect 
matches to the sub configuration including features in a subset. The algorithm can also 
optionally use information from inactive ligands to place excluded volume features. The 
HipHop algorithm reports the 10 top-scoring hypotheses until there is no improvement in 
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the hypothesis score. The resulting 10 pharmacophore hypotheses were used for the later 
steps of screening. 
3.4 Database Selection 
The database selected was DrugBank(112). DrugBank is a freely available web-
enabled database that combines detailed drug data with comprehensive drug-target and 
drug-action information. It was specifically designed to facilitate in silico drug-target 
discovery, drug design, drug-metabolism prediction, drug-interaction prediction, and 
general pharmaceutical education. The database contains 6264 molecules drug entries 
including 1465 FDA-approved small molecule drugs, 132 FDA-approved biotech 
(protein/peptide) drugs, 86 nutraceuticals and 5076 experimental drugs. Since the 
screening is to be carried out to aid in the discovery of drugs for Alzheimer’s disease, 
DrugBank was chosen as all the molecules will exhibit drug like property. All the available 
drug structures were used for the in-silico screening study. The structures of the drugs 
were downloaded in .sdf (Structural data file) format from the web database for use in the 
screening. 
3.5 Local Database Creation 
Database was created on the local workstation using the Build 3D database 
protocol in Discovery Studio 2.5. 6264 molecules were input for database creation. The 
database building was done with default parameters, except the conformation method was 
changed to FAST to get quick diverse low-energy conformations. During the building 
process 104 molecules showed error related to valency requirement or parsing error, hence 
were not included in the database created. Thus the final database created consisted of 




Figure 1 - Structure of compounds in training set. The two-dimensional chemical structure of 
56 compounds taken in the training set. The ChEMBL Id for the compounds has been used to 
denote the compounds. 
 
CHEMBL51698 CHEMBL51699 CHEMBL57146 CHEMBL58925 CHEMBL73841 CHEMBL115852 
CHEMBL117978 CHEMBL118450 CHEMBL119657 CHEMBL130093 CHEMBL133746 CHEMBL177969 
CHEMBL179519 CHEMBL180209 CHEMBL182327 CHEMBL182349 CHEMBL183449 CHEMBL183558 
CHEMBL183585 CHEMBL183654 CHEMBL183764 CHEMBL183777 CHEMBL191302 CHEMBL194084 
CHEMBL194422 CHEMBL194788 CHEMBL196523 CHEMBL198302 CHEMBL199570 CHEMBL199912 
CHEMBL200176 CHEMBL200503 CHEMBL200664 CHEMBL200864 CHEMBL200913 CHEMBL210279 
CHEMBL211896 CHEMBL291322 CHEMBL291976 CHEMBL332885 CHEMBL333710 CHEMBL336071 
CHEMBL362216 CHEMBL366022 CHEMBL369557 CHEMBL370107 CHEMBL371754 CHEMBL372156 




Table 1 - Training dataset for pharmacophore modelling for potential inhibitors of gamma-
secretase showing experimental activity (IC50) and the total no. of pharmacophore 








CHEMBL51698 15 14 
CHEMBL51699 93 14 
CHEMBL57146 32 8 
CHEMBL58925 1 15 
CHEMBL73841 6.9 13 
CHEMBL115852 57 11 
CHEMBL117978 5 11 
CHEMBL118450 47 11 
CHEMBL119657 86 11 
CHEMBL130093 0.49 14 
CHEMBL133746 13.2 13 
CHEMBL177969 50 10 
CHEMBL179519 15 20 
CHEMBL180209 1 19 
CHEMBL182327 34 16 
CHEMBL182349 41 19 
CHEMBL183449 70 12 
CHEMBL183558 7 20 
CHEMBL183585 75 18 
CHEMBL183654 50 15 
CHEMBL183764 12 20 
CHEMBL183777 62 16 
CHEMBL191302 27 14 
CHEMBL194084 18 19 
CHEMBL194422 17 16 
CHEMBL194788 1 20 
CHEMBL196523 19 19 








CHEMBL199570 1.9 11 
CHEMBL199912 1.1 13 
CHEMBL200176 1 10 
CHEMBL200503 1.3 10 
CHEMBL200664 4.2 20 
CHEMBL200864 4.2 26 
CHEMBL200913 10.7 19 
CHEMBL210279 6.18 28 
CHEMBL211896 55 10 
CHEMBL291322 29 13 
CHEMBL291976 71 26 
CHEMBL332885 38 11 
CHEMBL333710 14 11 
CHEMBL336071 1.8 15 
CHEMBL362216 29 16 
CHEMBL366022 22 10 
CHEMBL369557 5 20 
CHEMBL370107 10 19 
CHEMBL371754 0.82 18 
CHEMBL372156 35 9 
CHEMBL379089 0.08 26 
CHEMBL379758 77 10 
CHEMBL382060 1 12 
CHEMBL383826 4.7 18 
CHEMBL384207 0.9 24 
CHEMBL406322 4 10 
CHEMBL421236 76 13 
CHEMBL431679 5 17 
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3.6 Database Screening 
Instead of selecting a single pharmacophore hypothesis from the 10 hypotheses 
generated, all the pharmacophore hypotheses were used for screening the database created 
from the molecules obtained from DrugBank. The purpose of this screening is to retrieve 
hits for further screening. The database screening was carried out using Search 3D 
database protocol of Catalyst in Discovery Studio 2.5 with the query as the individual 
pharmacophore hypotheses; with default parameters except the search method was 
changed to FAST allowing a rigid fit of the ligand conformation against the 
pharmacophore. Thus 10 lists of compounds each corresponding to a pharmacophore 
could be obtained. Then a list with unique entires and entries with a Fit Value > 3.00 was 
prepared by merging all the lists of compounds obtained by screening DrugBank 
compounds with the pharmacophore as query. 
3.7 Activity prediction using QSAR 
The compounds in the training set were selected based on the available activity 
data i.e., experimental IC50 values. IC50 is the half maximal inhibitory concentration. It is 
a measure of effectiveness of a compound in inhibiting a biological function. It 
quantitatively gives the concentration of the drug or inhibitor required for the inhibition of 
a given biological process by half. FDA terms IC50 as the concentration of the drug 
required for 50% inhibition in vitro. IC50 can be related to affinity for competitive 
agonists and antagonists even though it is not direct indicator of affinity. The activity of 
the compounds (IC50) in the training set was for the production of Aβ-42 by cleaving of 
APP by gamma-secretase. Since the mechanism of action of gamma-secretase is known, 
the compound inhibits this biological process. The IC50 for the screened compound can 
be predicted by developing a QSAR model with the activity data of the training set of 
pharmacophore modeling as training set for QSAR model development. It is understood 
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that the development of a QSAR model which is a linear mathematical equation relating 
the biological activity of interest with the molecular descriptors of the compounds in the 
test set (unknown). 
3.8 Calculation of Molecular descriptors 
Molecular descriptors are required to be calculated for both the training set and the 
test set. The molecular descriptors were calculated for the compounds using e-Dragon 
tool. This tool can calculate over 3000 molecular descriptors which is lesser compared to 
the standalone dragon software. It required the input of the structure of the compound in 
SMILES or .sdf. The molecular descriptors were given as tab separated values. These were 
calculated and documented for both the test set and the training set. Some of the 
molecular descriptors calculated include number of rings (nCIC), number of rotable bonds 
(RBN), mean atomic polarizability (Mp), etc.  
3.9 Selection of Molecular descriptors 
The following molecular descriptors were selected from the list of over 3000 
descriptors. Sum of atomic van der Waals volumes (Sv), mean atomic van der Waals 
volume (Mv), mean atomic Sanderson electronegativity (Me), mean atomic polarizability 
(Mp), number of bonds (nBT), number of rings (nCIC), hydrophilic factor (Hy), 
Moriguchi octanol-water partition coefficient (MLogP) and Ghose-Crippen octanol-water 
partition coefficient (ALogP). Thus a total of nine molecular properties were selected. The 
no. of molecular properties is one-fifth of the number of compounds in the training set. 
This is because multiple linear regression is employed to develop the QSAR model to 
predict the biological activity of the test set of compounds. The reason behind this could 
be understood from the following theory on multiple linear regression. 
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3.10 Multiple Linear Regression 
Multiple linear regression is the most commonly employed method for 
constructing QSAR models. It is also a simple method. A multiple linear regression model 
is constructed with the assumption that a linear relationship exists between a set of 
molecular descriptors of a compound and a specific activity. The molecular descriptors are 
represented by a feature vector x with each descriptor as its component while the activity is 
represented by a quantity y.  The following equation is a description of multiple linear 
regression model. 
𝑦 = 𝛼0 + 𝛼1𝑋1 + 𝛼2𝑋2 + ⋯ . . +𝛼𝑛𝑋𝑛 
where 𝛼0 is the regression model constant, (𝑋1, 𝑋2, ….., 𝑋𝑛) are molecular descriptors, 
𝛼1 to 𝛼2 are the coefficients for the individual descriptors from 𝑋1 to 𝑋𝑛 . The values for 
𝛼0  to 𝛼𝑛  are chosen by minimizing the sum of squares of the residuals between the 
observed and predicted values defined by the equation so as to give the best prediction of 
𝑦 from x. This method has the advantage of having a simplistic form and being an easy 
interpretable expression. The positive or negative contribution of the molecular 
descriptors from 𝛼1 to 𝛼𝑛 is indicated by the sign of their respective coefficients. The 
relative importance of every descriptor to that activity is given by its magnitude. However, 
multiple linear regression works well only when the structure-activity relationship is linear 
in nature, the set of molecular descriptors are mathematically independent (orthogonal) of 
each another and the number of compounds in the training set exceeds the number of 
molecular descriptors by at least a factor of five. It has been found that, when collinear 
descriptors are used, the derived coefficients 𝛼1 to 𝛼𝑛  tend to be larger than the real 
values and sometimes have opposite signs. Therefore, the assumption of a linear 
relationship between a set of molecular descriptors and a specific activity may not always 
be appropriate, especially in the cases involving multiple mechanisms. 
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3.11 Developing QSAR model to predict IC50 
QSAR model was developed by using the tool EasyQSAR v1.0. It uses the 
statistics engine of Microsoft Excel to perform the regression analysis. This requires the 
input of experimental biological data. In order to keep the mean deviation in the data of 
biological data as small as possible log IC50 is given as biological activity. The values of the 
molecular descriptors are fed in the tool. After performing the regression analysis the 
QSAR model that is a linear mathematical equation is given.  
The QSAR model was then tested by substituting the test set molecular descriptor 
data in it. This was be used to validate the QSAR model by comparing the predicted and 
experimental activity data. Then the IC50 values were be predicted for the test set by 
substituting the values for the molecular descriptors in the QSAR model. The predicted 
IC50 values were used to filter the compounds for further screening.  
3.12 Docking study with SwissDock 
Docking study was carried out to find the binding of the ligand to the receptor. 
The challenge to carry out the study was the absence of complete three-dimensional 
structure of gamma-secretase complex. Sourcing of databases revealed the availability of 
structural data for the C-terminal fragment (CTF) of presenilin [PDB ID: 2KR6]. It had 
been identified that the catalytic core of the gamma-secretase complex is presenilin. The 
catalytic site of presenilin includes two aspartyl residues Asp 257 and Asp 285 on the 6th 
and 7th transmembrane domains respectively. The Asp 285 is present in the CTF of 
presenilin. Thus a compound that binds to Asp 285 or in the vicinity of Asp 285, block the 
binding of the substrate making it geometrically impossible. This involved the 
identification of binding site that possess Asp 285 using QsiteFinder tool(113).  The 
geometric co-ordinates of the binding site with Asp 285 were predicted by the tool. 
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The compounds obtained after the filtering based on predicted IC50 values were 
used in docking study. The docking study was carried out using SwissDock(114). 
SwissDock is an EADock DSS(115) based web server. The algorithm consists of the 
following steps generation of binding modes wither in box or in the vicinity of all target 
cavities, estimation of CHARMM energies on a grid, evaluation of binding modes with 
most favorable energies and clustered, visualization of the favorable clusters. It allows the 
docking of protein receptor with ligand molecules. It requires the input format of the 
receptor to be .pdb (Protein Data Bankk) and that or ligand to be .mol2. These file format 
conversion were done using OpenBabel 2.3.1. The ligand and receptor files, minimized 
energetically, in the appropriate format were uploaded to the web-based server for docking 
study. The results contained the estimated free energy of binding (∆G) and Full fitness 
score, besides the conformation of the ligand docked to the receptor. The lower estimated 
free energy of binding indicates the higher binding affinity. The compounds were again 
screened based on the estimated free energy of binding. The screening hits are suggested 





4.1 Pharmacophore Modeling  
The resulting pharmacophore hypotheses generated using the training set of active 
gamma-secretase inhibitors had a max fit score of 4 with rank ranging from 249.565 to 
256.150 with the pharmacophore features hydrophobic center (HY) and hydrogen bond 
acceptor (HBA) and a total of 4 features. The configuration of the pharmacophore 
hypotheses are presented in (Figure 2) while (Table 2) gives the details of each hypothesis.  
Table 2 - Pharmacophore hypotheses generated with the features present in the 
pharmacophore model and the maximum fit score along with the rank of each hypotheses. 
Pharmacophore 
hypotheses Features Rank Max Fit 
01 HY HY HBA HBA 256.150 4 
02 HY HY HBA HBA 253.297 4 
03 HY HY HBA HBA 252.572 4 
04 HY HY HBA HBA 252.518 4 
05 HY HY HBA HBA 251.107 4 
06 HY HY HBA HBA 251.098 4 
07 HY HY HBA HBA 251.004 4 
08 HY HY HBA HBA 250.902 4 
09 HY HY HBA HBA 250.813 4 
10 HY HY HBA HBA 249.565 4 
 







1 2 3 
4 5 6 
7 8 9 
10 
Figure 2 - Pharmacophore hypotheses generated. The input of 56 training set molecules 
gave 10 pharmacophore hypotheses. The pharmacophore hypotheses have hydrophobic, HY 
(cyan) and hydrogen bond acceptor, HBA (green). The total no. of features in each hypothesis 
is 4 (2 HY, 2 HBA). 
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4.2 Database Screening 
4.2.1 Pharmacophore search 
The screening of 6160 compounds from DrugBank with the pharmacophore 
hypotheses as query resulted in a reduced number of molecules than in total number of 
molecules in the database. No one hypotheses could be used alone as all the models had 
the same type of and the same number of pharmacophore features. Each hypothesis 
namely hypothesis 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 produced 1270, 1206, 1431, 1373, 1696, 
1372, 1682, 1569, 1433 and 1832 hits in the screening process. The merging of the 
compound lists into another list with only compounds with fit value above 3.00 and 
unique entries contained 721 compounds. This list along with the fit value of the 
molecules is given in (Table 3) 
4.3 Activity prediction using QSAR 
The training set consisting of 54 compounds with experimental activity data (IC50) 
and molecular descriptor data was used to develop QSAR model. The training set 
compounds along with their experimental activity and with molecular descriptor data is 
given in (Table 4). EasyQSAR tool yielded a QSAR model upon input of data and 
followed by analysis. The following model was developed and can be used to predict IC50 
of the 721 compounds in the test set. The QSAR model was validated by substituting the 
values of the training set in it. Thus the difference in experimental and predicted data was 
obtained. The values are given in (Table 6). The molecular descriptors of the compounds 
in the test set were calculated, and used to predict the IC50 value using the QSAR model. 
Their predicted IC50 values are given in (Table 7). The predicted IC50 ranged from 3.81E-
08 to 3.60E+118. The IC50 prediction of DB00014 yielded no result due to erroneous 
values for molecular descriptors. 
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Table 3 – List of compounds screened from DrugBank using the pharmacophore 
hypotheses with Fit value > 3.0000 while 4.0000 is the maximum fit value































































































































































































































































































































































































































































































































































































































































































































































Table 4 – Training Set compounds of QSAR model development with activity (IC50) and 
molecular descriptor data (Sv, Mv, Me, Mp, nBt, nCIC, Hy, MLogP, ALogP) 
Compound Id log IC50 Sv Mv Me Mp nBT nCIC Hy MLogP ALogP 
CHEMBL51698 1.176091 38.19 0.67 1.01 0.7 60 4 0.811 3.668 3.934 
CHEMBL51699 1.968483 38.19 0.67 1.01 0.7 60 4 0.811 3.668 3.934 
CHEMBL57146 1.50515 40.5 0.58 1 0.61 71 2 0.192 3.398 4.549 
CHEMBL58925 0 45.58 0.57 0.99 0.61 81 2 0.763 2.503 4.824 
CHEMBL73841 0.838849 38.91 0.65 1.02 0.67 63 4 0.162 4.289 4.235 
CHEMBL115852 1.755875 37.31 0.62 1.01 0.65 62 3 0.222 2.494 1.956 
CHEMBL117978 0.69897 34.22 0.63 1.03 0.65 56 3 0.27 2.447 1.435 
CHEMBL118450 1.672098 37.42 0.62 1.02 0.65 62 3 0.235 2.866 2.162 
CHEMBL119657 1.934498 35.11 0.62 1.01 0.64 59 3 0.257 1.031 1.146 
CHEMBL130093 -0.3098 39.31 0.66 1.02 0.68 63 4 0.801 3.866 4.144 
CHEMBL133746 1.120574 38.83 0.66 1.02 0.68 63 5 -0.355 3.936 4.909 
CHEMBL177969 1.69897 36.63 0.61 1.02 0.64 61 2 0.208 3.759 3.92 
CHEMBL179519 1.176091 36.46 0.66 1 0.72 59 5 -0.329 3.857 4.513 
CHEMBL180209 0 38.77 0.64 1 0.69 65 5 -0.341 3.403 4.598 
CHEMBL182327 1.531479 27.39 0.67 1.02 0.73 44 4 -0.26 3.925 4.574 
CHEMBL182349 1.612784 38.76 0.63 1 0.68 65 4 0.239 3.097 4.406 
CHEMBL183449 1.845098 28.19 0.64 1 0.68 47 4 -0.342 3.809 4.329 
CHEMBL183558 0.845098 38.17 0.64 1 0.69 64 5 0.239 3.097 4.17 
CHEMBL183585 1.875061 37.18 0.65 1 0.69 61 5 0.177 3.011 4.186 
CHEMBL183654 1.69897 26.57 0.65 1 0.71 44 4 -0.31 3.035 3.91 
CHEMBL183764 1.079181 36.37 0.67 1.01 0.72 58 5 0.239 3.143 4.431 
CHEMBL183777 1.792392 27.28 0.67 1 0.73 44 4 -0.284 3.54 4.369 
CHEMBL191302 1.431364 24.32 0.66 1.04 0.7 38 2 -0.198 3.345 4.057 
CHEMBL194084 1.255273 40.59 0.6 1.01 0.64 72 5 -0.334 4.547 5.055 
CHEMBL194422 1.230449 24.81 0.62 1.04 0.66 43 4 -0.198 3.218 4.473 
CHEMBL194788 0 38.77 0.64 1 0.69 65 5 -0.341 3.403 4.598 
CHEMBL196523 1.278754 39.17 0.59 0.99 0.64 70 5 -0.361 3.262 3.438 
CHEMBL198302 0.531479 37.9 0.6 1.02 0.64 67 5 -0.292 3.367 3.573 
CHEMBL199570 0.278754 30.03 0.65 1.04 0.69 48 3 0.318 3.823 4.662 
CHEMBL199912 0.041393 34.91 0.63 1.03 0.69 57 3 -0.671 4.182 5.076 
CHEMBL200176 0 35.23 0.65 1.03 0.69 57 4 -0.712 4.601 4.595 
CHEMBL200503 0.113943 32.71 0.64 1.02 0.68 53 3 -0.302 4.638 4.555 
CHEMBL200664 0.623249 31.72 0.65 1.03 0.7 51 3 -0.234 3.749 4.21 
CHEMBL200864 0.623249 31.72 0.65 1.03 0.7 51 3 0.33 3.749 4.263 
CHEMBL200913 1.029384 27.52 0.66 1.03 0.7 44 3 -0.277 4.459 4.493 
CHEMBL210279 0.790988 32.11 0.66 1.04 0.7 52 4 0.342 4.195 3.246 
CHEMBL211896 1.740363 28.52 0.66 1.03 0.71 45 3 -0.722 4.606 4.936 
CHEMBL291322 1.462398 37.71 0.66 1.02 0.68 60 4 0.82 3.668 3.681 
CHEMBL291976 1.851258 34.81 0.61 1 0.64 59 3 1.595 2.068 2.586 
CHEMBL332885 1.579784 35.11 0.62 1.01 0.64 59 3 0.257 1.031 0.854 
CHEMBL333710 0.255273 37.23 0.66 1.03 0.68 60 5 0.191 3.738 4.704 
CHEMBL336071 1.462398 27.39 0.67 1.02 0.73 44 4 -0.26 3.925 4.574 
CHEMBL362216 0.69897 38.28 0.63 1.01 0.68 65 5 -0.31 2.768 4.179 
CHEMBL366022 1 27.52 0.66 1.03 0.7 44 3 -0.277 4.459 4.493 
CHEMBL369557 -0.08619 34.91 0.63 1.03 0.69 57 3 -0.265 4.182 5.082 
CHEMBL370107 1.544068 31.12 0.65 1.03 0.69 50 3 -0.288 4.423 4.224 
CHEMBL371754 -1.09691 34.31 0.65 1.03 0.7 56 4 -0.265 4.182 4.495 
CHEMBL372156 1.886491 28.52 0.66 1.03 0.71 45 3 -0.722 4.606 4.936 
CHEMBL379089 0 32.11 0.64 1.03 0.68 52 3 0.96 4.041 4.345 
CHEMBL379758 0.672098 29.12 0.65 1.03 0.69 47 3 -0.294 4.682 4.823 
CHEMBL382060 -0.04576 33.71 0.65 1.03 0.7 55 4 -0.233 4.413 3.782 
CHEMBL383826 0.60206 40.48 0.61 1 0.65 68 3 0.206 2.403 2.644 
CHEMBL384207 1.880814 37.31 0.65 1.02 0.68 60 4 0.177 3.417 3.491 
CHEMBL406322 0.69897 37.93 0.62 1.03 0.64 63 3 0.877 2.127 1.616 
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QSAR model to predict IC50 value of potential inhibitors of gamma secretase from 
DrugBank 
logIC50 = 5.333468493034E+001 + 9.441980133615E–002*Sv 
 + 1.615431581663E+001*Mv + – 4.127786888796E+001*Me 
 + –2.451283848884E+001*Mp + –1.253675687200E–001*nBT 
 + 3.276417714217E–002*nCIC + –1.388896872996E–001*Hy 
 + 4.968101794863E–002*MLOGP + –1.111794822900E–001*ALOGP 
The following table serves to give a brief account of the various terms in the QSAR model 
developed to predict IC50. 
Table 5 - Molecular descriptors used in QSAR model along with its coefficient and input 
data range 
Descriptor Explanation Range Coefficient 
Sv sum of atomic van der Waals volumes 24.320 – 45.580 9.441980133615E–002 
Mv mean atomic van der Waals volume 00.570 – 00.670 1.615431581663E+001 
Me mean atomic Sanderson electronegativity 00.990 – 01.040 –4.127786888796E+001 
Mp mean atomic polarizability 00.610 – 00.730 –2.451283848884E+001 
nBT number of bonds 38.000 – 81.000 –1.253675687200E–001 
nCIC number of rings 02.000 – 05.000 3.276417714217E–002 
Hy hydrophilic factor -00.722 –  01.595 –1.388896872996E–001 
MLOGP Moriguchi octanol-water partition coeffecient 01.031 – 04.682 4.968101794863E–002 
ALOGP Ghose-Crippen octanol-water partition coeffecient 00.854 – 05.082 –1.111794822900E–001 
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Figure 3 - Plot of Actual activity data (log IC50) vs Predicted activity data (log IC50) 
Table 6 - Validation of QSAR model. Actual activity data (log IC50) and Predicted Activity 
data (log IC50)
Compound Id Actual IC50 Predicted IC50 
CHEMBL51698 1.18       1.16 
CHEMBL51699 1.97       1.16 
CHEMBL57146 1.51       1.10 
CHEMBL58925 0.00       0.42 
CHEMBL73841 0.84       0.93 
CHEMBL115852 1.76       1.45 
CHEMBL117978 0.70       1.30 
CHEMBL118450 1.67       1.04 
CHEMBL119657 1.93       1.88 
CHEMBL130093 -0.31       0.79 
CHEMBL133746 1.12       0.86 
CHEMBL177969 1.70       1.00 
CHEMBL179519 1.18       1.01 
CHEMBL180209 0.00       0.86 
CHEMBL182327 1.53       1.08 
CHEMBL182349 1.61       0.84 
CHEMBL183449 1.85       2.38 
CHEMBL183558 0.85       0.88 
CHEMBL183585 1.88       1.33 
CHEMBL183654 1.70       2.04 
CHEMBL183764 1.08       0.78 
CHEMBL183777 1.79       1.91 
CHEMBL191302 1.43       1.25 
CHEMBL194084 1.26       0.33 
CHEMBL194422 1.23       1.02 
CHEMBL194788 0.00       0.86 
CHEMBL196523 1.28       1.23 
CHEMBL198302 0.53       0.39 
CHEMBL199570 0.28       0.54 
CHEMBL199912 0.04       0.07 
CHEMBL200176 0.00       0.53 
CHEMBL200503 0.11       1.21 
CHEMBL200664 0.62       0.61 
CHEMBL200864 0.62       0.53 
CHEMBL200913 1.03       1.26 
CHEMBL210279 0.79       0.35 
CHEMBL211896 1.74       1.01 
CHEMBL291322 1.46       1.05 
CHEMBL291976 1.85       1.80 
CHEMBL332885 1.58       1.91 
CHEMBL333710 0.26       0.60 
CHEMBL336071 1.46       1.08 
CHEMBL362216 0.70       0.50 
CHEMBL366022 1.00       1.26 
CHEMBL369557 -0.09       0.01 
CHEMBL370107 1.54       0.96 
CHEMBL371754 -1.10       0.25 
CHEMBL372156 1.89       1.01 
CHEMBL379089 0.00       0.68 
CHEMBL379758 0.67       1.10 
CHEMBL382060 -0.05       0.41 
CHEMBL383826 0.60       1.17 
CHEMBL384207 1.88       0.95 
CHEMBL406322 0.70       0.73 
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No. of compounds with Predicted IC50 under 1nM  = 42 
No. of compounds with Predicted IC50 under 10nM  = 119 
No. of compounds with Predicted IC50 under 100nM = 272 
No. of compounds with Predicted IC50 under 1000nM = 394 
No. of compounds with Predicted IC50 under 10000nM = 498  
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4.4 Docking study 
4.4.1 Binding site definition 
The binding sites were defined using QsiteFinder. The binding site with Asp 385 
was identified. Its geometric co-ordinates were noted as x= -5, y=72, z=-14, X=11, Y= 86, 
Z=1. These define the box for binding analysis in the docking program.  
 
Figure 4 - Binding site with Asp 385 predicted using QsiteFinder on the CTF of presenilin 
(2KR6). The binding site’s surface is marked in purple, while Asp 385 is marked in cyan. 
4.4.2 Docking using SwissDock 
Docking was performed with SwissDock. The receptor was CTF of Presenilin 
2KR6 while the 498 compounds with predicted IC50 >=10000 nM, were the ligands used. 
The binding box was defined with the geometric co-ordinates predicted using QsiteFinder 
tool, x= -5, y=72, z=-14, X=11, Y= 86, Z=1. Docking study yielded 55 compounds with 
estimated free energy of binding lesser than -8.00 kcal/mol (Figure 5a & 5b). The range of 
estimated free energy of binding is  -12.39 kcal/mol to -5.20 kcal/mol. The attempt to 
perform docking studies failed for 51 compounds either due to complexity of the ligand 
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structure for the docking program or due to loss of data due to the crashing of docking 
program. 
 
DB02777 DB01263 DB00471 DB00206 
DB02549 DB02477 DB01167 DB08180 
DB08376 DB07349 DB01396 DB02169 
DB03031 DB00691 DB01258 DB00688 
DB08499 DB08585 DB00203 DB00549 
DB01329 DB07836 DB04542 DB01991 
Figure 5a – Hits of docking study and estimated free energy of binding screen ∆G 





DB07780 DB07765 DB03336 DB00932 
DB01083 DB08810 DB00718 DB01254 
DB08342 DB06717 DB07264 DB00559 
DB07362 DB07394 DB01871 DB07165 
DB08721 DB01419 DB00177 DB08477 
DB08404 DB08762 DB00178 DB07974 
DB01319 DB04695 DB07947 DB00948 
DB01321 DB01411 DB00528 
Figure 5b – Hits of docking study and estimated free energy of binding screen, ∆G 
<= -8.00 kcal/mol for the compounds with predicted IC50 <=10000nM 
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Table 8 – Result of docking study showing estimated free energy of binding for the 













































































































































































































































































































































































































































































Screening of 6160 compounds from DrugBank database using various filters 
namely pharmacophore search, predicted biological activity (IC50) and docking study was 
carried out. At the end of each screening a significant amount of compounds of non-
interest were eliminated from the overall screening process. There were 721 compounds 
after application of pharmacophore screen. After the application of biological activity 
screen 498 compounds were taken for further screening. These compounds were screened 
based on the estimated free energy of binding (∆G) after being subjected to docking 
study.Finally, 54 compounds were left. These compounds belonged to various classes 
namely Phenylpropenes, Phenethylamines, Anisoles, Alkaloids and Alkaloid Derivatives, 
Steroids and Steroid derivatives, Phenylpropylamines, Salicylates and Derivatives, 
Benzenesulfonamides, Pyrans, Lactones, Benzamide, Purine and purine derivatives, 
Piperazines, Halobenzenes, Biphenyltetrazoles and Derivatives, Aminoglycosides, 
Chromones and Diphenylmethanes. Of these classes of compounds a few have already 
been associated with inhibition of gamma-secretase namely sulfonamides (61, 98, 99, 109). 
The occurrence of this class of compounds in the study reaffirms the potential of these 
compounds. Also a few of the compounds classes have not yet been reported as potential 
inhibitors of gamma secretase namely piperazine, phenylpropylamine, and anisoles. Also a 
few of the hits are anti-hypertensive drugs. This class of drugs has already been studied for 
therapy of Parkinson’s disease(116). Despite the differing mechanisms of pathogenesis of 
Alzhiemer’s disease and Parkinson’s disease, it is inferred that further study of anit-
hypertensive drugs for development of therapy of Alzheimer’s may produce potential 
drugs. Further study of these classes of compounds may produce a novel class of 
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